Paxman AB (B0F) AI Stock Analysis

Paxman AB

(Frankfurt:B0F)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong revenue growth and demandRapid sales growth and a sizeable order book indicate expanding adoption of scalp-cooling systems across treatment sites. This supports forward revenue visibility, strengthens the company’s market position, and provides a foundation for recurring consumables and service revenue.

Negative Factors

Losses and negative cash generationCurrent losses and negative operating and free cash flow show that growth is not yet being funded by internal cash generation. If this persists, liquidity could be consumed more quickly and management may have less flexibility to finance expansion and product programs.

Paxman AB (B0F) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 81.46M
Dividend Yield: ―
Average Volume (3M): 781
Price to Earnings (P/E): -303.8
Beta (1Y): 0.22
Revenue Growth: 38.49%
EPS Growth: -148.51%
Country: Germany
Employees: 151
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

Paxman AB Business Overview & Revenue Model

Company Description

Paxman AB (publ), along with its subsidiaries, specializes in the creation and worldwide sale of the Paxman scalp cooling system, an innovative solution designed to minimize hair loss in patients undergoing chemotherapy. This system is distributed ac...

Paxman AB Earnings Call Summary

Earnings Call Date:Aug 20, 2026(Q2-2026)|% Change Since:43.49%|Next Earnings Date:Nov 19, 2026

Earnings Call SentimentPositive

The call highlights strong commercial momentum: record quarterly sales (+40% YoY), substantial U.S. revenue growth (~+77.5% YoY), large increases in insurance-based billing (110%), improved adjusted margins (~19%), a robust order book (190 systems, 80 in U.S.), and a healthy cash position (SEK 105m). These positives are tempered by a regulatory setback for the neuropathy device (shift to De Novo with an 8–12 month review window), increased operating and CIPN-related costs (OpEx up ~SEK 6m q/q; CIPN costs up ~30%), and a slower near-term U.S. rollout for CIPN. Overall, company fundamentals and commercial traction are strong and appear to outweigh the regulatory and cost challenges, but the De Novo timeline introduces meaningful near-term uncertainty for the new product launch.

Positive Updates

Record Group Sales and Strong YoY Growth

Group sales totaled just over SEK 105 million, the first time exceeding SEK 100 million, representing approximately 40% year-on-year growth.

Negative Updates

Regulatory Setback and Timeline Delay for Neuropathy Device

FDA determined there is no suitable predicate, requiring a De Novo submission rather than the planned 510(k). This introduces delay: expected FDA review 8–12 months with commercialization now targeted for Q2 2027 (clearance potentially April–August 2027).

Company Guidance

Guidance from the call (Q2 FY2026) flagged concrete near‑term targets and key metrics: group sales were just over SEK 105m (≈40% YoY growth) with EBITDA around SEK 14m (Dignitana contributing ~SEK 5.2m), adjusted EBITDA margin ~18.5% (13% including CIPN costs), cash ≈SEK 105m on the balance sheet and ~SEK 5m movement in available cash. Operational datapoints: 56 systems delivered in Q2, 1,326 caps sold via insurance‑based billing (IBBM) as IBBM revenue grew ~110%, order book at 190 systems (80 in the U.S.), and utilization markedly higher under IBBM (8.6 patients/site, 3.4 patients/system) vs self‑pay (3.1/site, 1.6/system). CIPN program: De Novo submission planned this month with an FDA review horizon of ~150 days (overall 8–12 months expected) targeting U.S. commercialization in Q2 2027; build plan includes 50 units already deployed for pilots and up to 150 units with V2 commercial units to start production in Q4 (Oct–Dec). Costs and working capital: OpEx rose ~SEK 6m Q1→Q2 with CIPN/other costs ~SEK 5.6m this quarter (vs SEK 4.3m prior), and management reiterated Europe roll‑out plans (Sept in DE/FR/ES/NL) and a CapEx+consumables commercial model for neuropathy.

Paxman AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:B0F against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:XVIVO	64Neutral	SEK 6.46B	50.12	5.89%	―	17.83%	330.94%
SE:SEZI	57Neutral	SEK 532.17M	-5.46	-35.44%	―	18.56%	28.11%
SE:BACTI.B	53Neutral	SEK 560.70M	88.89	1.93%	―	-0.51%	―
SE:BRAIN	53Neutral	SEK 410.67M	-8.95	-22.23%	―	6.49%	25.03%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:SEDANA	49Neutral	SEK 926.81M	-26.86	-3.88%	―	0.42%	15.03%

* Healthcare Sector Average

Performance Comparison

DE:B0F and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:B0F	Paxman AB	5.79	-0.31	-5.08%
SE:SEZI	Senzime AB	3.38	-2.45	-41.94%
SE:XVIVO	Xvivo Perfusion AB	205.00	22.50	12.33%
SE:BACTI.B	Bactiguard Holding AB	16.00	-1.00	-5.88%
SE:BRAIN	BrainCool AB	1.04	0.45	76.27%
SE:SEDANA	Sedana Medical AB	9.33	-0.83	-8.17%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Paxman AB AI Stock Analysis